Alexa Fluor® 568 Anti-CD8 antibody [SP239],Abcam,AB313089

What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Host

Rabbit

Reactivity

Human

Application

Target Binding Affinity, Antibody Labelling, IHC-P

Conjugate

Alexa Fluor® 568

Platform ID

BAB920437502

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAlexa Fluor® 568 Anti-CD8 antibody [SP239]
Cat. No.AB313089
HostRabbit
IsotypeIgG
ReactivityHuman
ConjugationAlexa Fluor® 568
ApplicationTarget Binding Affinity, Antibody Labelling, IHC-P
ClonalityMonoclonal
Clone NumberSP239
Concentration0.5 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data The protein expressed by the gene CD8A is an integral membrane glycoprotein crucial for immune responses, operating mainly in T-cells as a coreceptor for MHC class I molecule : peptide complexes. These peptides originate from cytosolic proteins, unlike class II peptides, which are from extracellular proteins. CD8A interacts with the T-cell receptor (TCR) and MHC class I proteins on antigen-presenting cells, recruiting the Src kinase LCK to the TCR-CD3 complex. LCK phosphorylates substrates, triggering signaling pathways that lead to the production of lymphokines, enhanced motility, adhesion, and activation of cytotoxic T-lymphocytes (CTLs), thereby aiding in the recognition and elimination of infected or tumor cells. Additionally, in natural killer (NK) cells, CD8A homodimers on the cell surface provide a survival mechanism for conjugating with and lysing multiple target cells. CD8A homodimers also facilitate the survival and differentiation of activated lymphocytes into memory CD8 T-cells. This supplementary information is collated from multiple sources and compiled automatically. See full target information CD8A

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.